China’s CanSinoBIO H1 revenue drops on weaker COVID shot demand
BEIJING: China's CanSino Biologics reported a 69.5 per cent drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by ...